2023
Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma
Lu L, Risch E, Halaban R, Zhen P, Bacchiocchi A, Risch H. Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. International Immunopharmacology 2023, 118: 110092. PMID: 37004344, DOI: 10.1016/j.intimp.2023.110092.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeSoluble PD-L1 (sPD-L1) levelsPD-L1 ratioPD-L1 levelsSoluble PD-1Soluble PD-L1PD-L1PD-1Patient survivalSurvival statusPD-1/PD-L1Immune checkpoints PD-1T cell exhaustionPatients' survival statusSolid tumor typesInitial immunotherapyCheckpoint blockadeMelanoma patientsPoor prognosisRetrospective studyPatient responseCell exhaustionTumor typesMelanomaSurvival
2016
Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer
Fu Y, Biglia N, Wang Z, Shen Y, Risch HA, Lu L, Canuto EM, Jia W, Katsaros D, Yu H. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer. Gynecologic Oncology 2016, 143: 642-649. PMID: 27667152, PMCID: PMC5507336, DOI: 10.1016/j.ygyno.2016.09.021.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinoma, Clear CellAdultAgedAged, 80 and overCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialHumansMiddle AgedNeoplasm GradingNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionRNA, Long NoncodingYoung AdultConceptsEpithelial ovarian cancerOvarian cancerStage diseasePatient survivalGrade tumorsASAP1-IT1Survival associationsLong non-coding RNAsCox proportional hazards regression modelPrimary epithelial ovarian cancerProportional hazards regression modelsTumor samplesFresh frozen tumor samplesHigh expressionEarly-stage diseaseFavorable overall survivalLate-stage diseaseHazards regression modelsLow-grade tumorsHigh-grade tumorsOvarian cancer progressionNon-coding RNAsImportant biological actionsOverall survivalPoor prognosis
2015
Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer. European Journal Of Gynaecological Oncology 2015, 36: 260-7. PMID: 26189250.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedBiomarkers, TumorCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialFemaleHumansImmunohistochemistryMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPhosphoric Monoester HydrolasesPrognosisProportional Hazards ModelsPTEN PhosphohydrolaseTumor Suppressor Protein p53Young AdultConceptsAberrant p53 expressionOvarian cancerP53 expressionHazard ratioLoss of PTENOvarian tumorsOvarian cancer tissue samplesEndometrioid ovarian tumorsProtein expressionSurvival hazard ratioEpithelial ovarian tumorsPoor disease outcomePossible prognostic roleProportional hazards modelCancer tissue samplesPrognostic roleEndometrioid tumorsEndometrioid subtypePrognostic valuePoor prognosisSerous subtypeProtein immunohistochemistryDisease outcomeTissue microarrayHazards model